Related Experiment Video

Updated: Aug 12, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

CD52 is not a promising immunotherapy target for most patients with multiple myeloma

Jörg Westermann1, Georg Maschmeyer, Antje van Lessen

  • 1Department of Hematology and Oncology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany. joerg.westermann@charite.de

International Journal of Hematology
|October 7, 2005
PubMed

Insights

CD52 is not a promising target for multiple myeloma antibody therapy. Most myeloma cells do not express CD52, limiting the effectiveness of treatments targeting this molecule.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma is a cancer of plasma cells.
  • Identifying effective molecular targets for antibody therapy is crucial for improving patient outcomes.
  • CD52 is a cell surface antigen that has been targeted in other hematological malignancies.

Purpose of the Study:

  • To evaluate the expression of CD52 on multiple myeloma cells.
  • To determine the potential of CD52 as a target for antibody-based therapies in multiple myeloma.

Main Methods:

  • Bone marrow samples from 20 multiple myeloma patients were analyzed.
  • Flow cytometry was used to assess the expression of CD45, CD38, CD138, CD3, CD19, and CD52 on myeloma cells.

Main Results:

  • The majority of multiple myeloma cells (CD45-CD38++) did not express CD52.
  • CD52 expression was detected only in a small subpopulation of plasma cells (CD45+CD38++).
  • This CD52-expressing subpopulation may represent a proliferative progenitor cell pool.

Conclusions:

  • CD52 is not a suitable molecular target for antibody therapy in most multiple myeloma patients.
  • Targeting CD52 in multiple myeloma would be a highly experimental approach with limited efficacy.
  • Further research is needed to identify more effective therapeutic targets for multiple myeloma.

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.